Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D | Starlite/ChEMBL | No references |
Giardia intestinalis | Putative fructose-1,6-bisphosphate aldolase | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium ulcerans | fructose-bisphosphate aldolase | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 361 aa | 26.9 % |
Mycobacterium tuberculosis | Probable fructose-bisphosphate aldolase Fba | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 361 aa | 25.5 % |
Candida albicans | fructose-bisphosphate aldolase | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 358 aa | 22.6 % |
Mycobacterium leprae | Probable fructose bisphosphate aldolase Fba | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 361 aa | 25.8 % |
Candida albicans | fructose-bisphosphate aldolase | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 358 aa | 22.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Mycobacterium leprae | Probable fructose bisphosphate aldolase Fba | 0.0172 | 0.4702 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.0019 | 0.0186 | 0.0336 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.0186 | 0.5 |
Mycobacterium tuberculosis | Probable fructose-bisphosphate aldolase Fba | 0.0172 | 0.4702 | 1 |
Brugia malayi | bZIP transcription factor family protein | 0.0248 | 0.6918 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0019 | 0.0186 | 0.027 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0248 | 0.6918 | 1 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Echinococcus multilocularis | jun protein | 0.0248 | 0.6918 | 1 |
Toxoplasma gondii | exonuclease III APE | 0.0019 | 0.0186 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0019 | 0.0186 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0019 | 0.0186 | 0.027 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0.0186 | 0.5 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0019 | 0.0186 | 0.0278 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.0186 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0019 | 0.0186 | 0.5 |
Brugia malayi | hypothetical protein | 0.0195 | 0.5356 | 0.7741 |
Schistosoma mansoni | ap endonuclease | 0.0019 | 0.0186 | 0.0336 |
Mycobacterium ulcerans | fructose-bisphosphate aldolase | 0.0172 | 0.4702 | 1 |
Onchocerca volvulus | 0.0182 | 0.4997 | 0.933 | |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0248 | 0.6918 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0.0186 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0182 | 0.4997 | 0.7223 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Echinococcus granulosus | jun protein | 0.0248 | 0.6918 | 1 |
Giardia lamblia | Fructose-bisphosphate aldolase | 0.0353 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0182 | 0.4997 | 0.7437 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0019 | 0.0186 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Onchocerca volvulus | 0.0195 | 0.5356 | 1 | |
Entamoeba histolytica | fructose-1,6-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Schistosoma mansoni | jun-related protein | 0.0201 | 0.5555 | 1 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0019 | 0.0186 | 0.027 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 1 |
Treponema pallidum | fructose-bisphosphate aldolase | 0.0353 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0201 | 0.5555 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0241 | 0.6719 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 6.2946 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia. (Class of assay: confirmatory) [Related pubchem assays: 2472, 2464 ] | ChEMBL. | No reference |
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Vif-A3F Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | 35.4813 uM | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 84.9214 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.